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http:WHAT THIS PAPER ADDS
A contemporary summary of clinical and/or imaging based scoring systems, predictive algorithms and imaging
parameters that may be associated with an increased (or decreased) risk of late stroke in patients with
asymptomatic carotid disease.Background: The 2011 American Heart Association Guidelines on the management of asymptomatic carotid
disease recommends that carotid endarterectomy (CEA) (with carotid artery stenting (CAS) as an alternative) may
be considered in highly selected patients with 70e99% stenoses. However, no guidance was provided as to what
“highly selected” meant. This caveat is, however, important as up to 95% of asymptomatic individuals undergoing
prophylactic CEA or CAS will ultimately undergo an unnecessary procedure. Even if the procedural risk following
CEA or CAS could be reduced to 0%; 93% of patients would still undergo an unnecessary intervention. This,
coupled with growing awareness that the risk of stroke in medically treated patients appears to be diminishing,
has led to a renewed drive towards identifying patients with the highest risk of suffering a stroke whilst on
medical therapy in whom to target CEA/CAS.
Methods: Review of clinical and/or imaging based scoring systems, predictive algorithms and imaging parameters
that may be associated with an increased (or decreased) risk of stroke in patients with asymptomatic carotid
disease.
Results: Parameters associated with an increased risk of late stroke include: (a) silent infarction on CT/MRI; (b)
stenosis progression; (c) hypoechoic plaques or GSM <15; (d) irregular plaques; (e) evidence of spontaneous
embolization on TCD; (f) AHA plaque types IVeV, VI; (g) MR diagnosed IPH; (h) plaque area >80 mm2; (i) juxta-
luminal black area >10 mm2; and (j) tandem intracranial disease.
Conclusions: A number of imaging parameters have been shown to be predictive of an increased risk of late
stroke in previously asymptomatic patients. None have been independently validated, but many could easily be
evaluated in natural history studies or randomized trials in order to identify a “high risk for stroke” cohort in
whom CEA/CAS could be prioritized.
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//dx.doi.org/10.1016/j.ejvs.2014.08.017Heart Association (AHA) Guidelines (published in 2011) rec-
ommends that all patients with asymptomatic 70e99% ca-
rotid stenoses should be offered risk factor control and
“optimal medical therapy” (Class I Recommendation, Level C
Evidence). They further advise that carotid endarterectomy
(CEA) was appropriate in highly selected patients, provided
the procedural risk was<3% (Class I Recommendation, Level
A Evidence) and that carotid artery stenting (CAS) might now
be considered appropriate in highly selected patients (Class
IIb Recommendation, Level B Evidence).1
Table 2. Temporal changes in the 5-year risk of “any” and
“ipsilateral” stroke in medically treated patients randomized
within ACAS and ACST.
Trial Year
published
Study
years
5-year rate
of “any” stroke
5-year rate of
“ipsilateral” stroke
ACAS 1995 1e5 17.5% 11.0%
ACST 2004 1e5 11.8% 5.3%
ACST 2010 6e10 7.2% 3.6%
Reproduced with permission from Naylor AR, Gaines PA, Rothwell
PM.7
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because the AHA did not deﬁne what this term meant. As a
consequence, there is evidence that some clinicians pay
little attention to this caveat,2 while others take it to mean
that the patient should simply have a predicted life-
expectancy of 3e5 years.3
There is no doubt that a small cohort of “high risk for
stroke” patients with asymptomatic carotid stenoses will
beneﬁt from CEA/CAS, but (to date) there have been limited
opportunities for deﬁning who these patients are. The aim
of this topical review was to ﬁrst summarise the random-
ized trial evidence that is used to justify interventions in
asymptomatic individuals, before reviewing contemporary
clinical, biochemical and imaging based strategies that
might be used in future natural history or randomized
studies to deﬁne a higher (or lower) risk cohort of patients
who might beneﬁt from CEA/CAS.
SUMMARY OF THE RANDOMIZED TRIALS
Table 1 details the 5-year risk of stroke (including peri-
operative stroke/death) in patients randomized to CEA or
best medical therapy (BMT) in the Asymptomatic Carotid
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid
Surgery Trial (ACST).4e6 Both trials reported a signiﬁcant
reduction in non-disabling stroke at 5 years, while ACST
reported a signiﬁcant reduction in disabling stroke. It has
traditionally been reported that both studies reported
similar outcomes (i.e., that CEA reduced the 5-year risk of
stroke by 50%). However, this is not the case. The “11%” 5-
year stroke risk in medically treated patients in ACAS refers
to “ipsilateral” stroke, while the “11.8%” 5-year stroke risk
in medically treated patients in ACST refers to “any” stroke.
ACST has now presented/published 5- and 10-year data
for “any” and “ipsilateral” stroke.7 When compared with
parallel data from ACAS, it makes interesting reading
(Table 2). The 5-year rate of “any” stroke in patients ran-
domized to BMT in ACAS (published in 1995) was 17.5%
(i.e., 3.5% pa). When ACST published its ﬁrst 5-year data in
2004, the 5-year rate of “any” stroke in medically treated
patients had fallen to 11.8% (2.4% pa). When ACST pub-
lished its 10-year data in 2010, the second 5-year rate of
“any” stroke had fallen even further to 7.2% (i.e., 1.4% pa).
Similarly, when ACAS published in 1995, the 5-year rate of
“ipsilateral” stroke in medically treated patients was 11.0%
(i.e., 2.2% pa). By 2004, the ﬁrst 5-year rate of “ipsilateral”
stroke in BMT patients randomized in ACST had decreased
to 5.3% (1.1% pa), falling to 3.6% for the second 5-yearTable 1. “Traditionally” published outcomes from ACAS and
ACST.4e6
Years
of FU
“Stroke” risk ARR Strokes prevented
per 1000 CEAsCEA BMT
ACASa 5 5.1% 11.0% 5.9% 59 @ 5 years
ACSTb 5 6.4% 11.8% 5.4% 54 @ 5 years
ACSTb 10 13.4% 17.9% 4.6% 46 @ 5 years
BMT ¼ best medical therapy; CEA ¼ carotid endarterectomy.
a In ACAS, the 5-year stroke risk refers to “any stroke.”
b In ACST, the 5- and 10-year data refer to “ipsilateral stroke.”period (0.7% pa).7 This represents a >60% decline in suc-
cessive ﬁve year rates of “any” and “ipsilateral” stroke and
would appear to corroborate data from contemporary, non-
randomized, natural history studies that the risk of stroke in
medically treated patients appears to be diminishing.8
WHO IS HIGH RISK FOR STROKE?
Although ACAS and ACST demonstrated that CEA conferred
a small, but signiﬁcant reduction in late stroke, it is an
indisputable fact that even with a procedural risk of <3%,
95% of all carotid interventions in asymptomatic patients
randomized within ACAS and ACST ultimately proved to be
unnecessary8 (Table 3). It has been suggested that reducing
the procedural risk after CEA and CAS will greatly improve
long-term stroke prevention.9 Unfortunately, this is not
correct. When the ACAS/ACST data in Table 3 are remod-
eled using a 0% procedural risk; 93% of all interventions
would still be unnecessary at 5 and 10 years respectively.8
This observation, coupled with growing awareness that
the annual risk of stroke in patients with asymptomatic
carotid stenoses treated medically appears to be diminish-
ing8 (see Table 2), has led to renewed efforts at identifying
clinical, imaging or biomarker algorithms for identifying the
truly “high-risk for stroke” asymptomatic patient in whom
to target CEA or CAS.Stenosis severity
Subgroup analyses from the European Carotid Surgery Trial
(ECST) and the North American Symptomatic Carotid End-
arterectomy Trial (NASCET) showed that stenosis severity
(but not near occlusion) was predictive of an increased risk
of late stroke in medically treated patients.10 However,
neither ACAS nor ACST found any evidence that (a)
increasing stenosis severity, (b) bilateral severe stenosis, or
(c) a severe stenosis and contralateral occlusion were pre-
dictive of an increased risk of late stroke in medically
treated patients.4,5 The Asymptomatic Carotid Stenosis and
Risk of Stroke (ACSRS) Study (1115 asymptomatic patients
with 50e99% stenoses) has reported that patients with
50e69% stenoses (ECST measurement method) incurred a
0.8% annual risk of ipsilateral stroke, increasing to 1.4% pa
for patients with 70e89% stenoses and 2.4% pa for those
with 90e99% stenosis.11 However, “best medical therapy”
in the 1998e2002 time period when ACSRS recruited their
patients was certainly much different to what would be
accepted in the modern era.
Table 3. Effect of modeling the procedural risk to 0% on preventing long-term stroke in ACAS and ACST.
30-day death/stroke
after CEA
Stroke rate including
30-day death/stroke
Strokes prevented
per 1000 CEAs
Unnecessary CEAs
per 1000 CEAs
CEA BMT
ACAS4 5 yrs 2.3% 5.1% 11.0% 59@5 yrs 941 (94%)
Modeled at 0.0% 2.8% 11.0% 82@5 yrs 918 (92%)
ACST5 5 yrs 2.8% 6.4% 11.8% 53@5 yrs 947 (95%)
Modeled at 0.0% 3.5% 11.8% 83@5 yrs 917 (92%)
ACST6 10 yrs 2.8% 13.4% 17.9% 46@10 yrs 954 (95%)
Modeled at 0.0% 10.5% 17.9% 74@10 y 926 (93%)
Note. The beneﬁts were calculated using the procedural risks observed in the constituent trial. They were then remodeled assuming a 0%
procedural risk to see whether this signiﬁcantly increased the number of strokes prevented. BMT ¼ best medical therapy; CEA ¼ carotid
endarterectomy.
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ACST found no evidence that asymptomatic patients aged
>75 years gained any beneﬁt from prophylactic CEA.5 In the
ACSRS Study, a history of contralateral TIA/stroke was
associated with a 3.4% annual risk of stroke, compared with
1.2% in patients with no previous symptoms.11 ACST has
also reported that medically treated patients with a history
of contralateral symptoms prior to randomization were
signiﬁcantly more likely to develop neurological symptoms
within 5 years in the territory ipsilateral to the asymp-
tomatic stenosis (29% risk at 5 years), compared to 22% in
those with no history of contralateral symptoms (OR 1.66,
95% CI 1.28e2.15, p < .001).12Stenosis progression
It is often assumed that stenosis progression is synonymous
with plaque instability and that this will be associated with
increased stroke risk. Despite the strength of this opinion,
surprisingly few observational studies have demonstrated
stenosis progression to be a risk factor for late stroke in
asymptomatic patients. This, however, is more likely to
reﬂect “absence of evidence rather than evidence of
absence”.
Sabetai et al.13 observed that stenosis progression was
associated with a twofold increase in the 3-year risk of
stroke from 2.5% to 5% (OR 2.00; 95% CI 1.02e4.11). In
practical terms, this equates to a 1.7% annual risk of stroke
in patients with stenosis progression, compared to 0.7% pa
in those without (i.e., not a very discriminating parameter).
The ACSRS has reported a subgroup analysis regarding
stenosis regression and progression in their 1000þ patientTable 4. Relationship between yearly change in stenosis severity catego
ipsilateral neurological event in patients randomized to medical thera
Yearly change in stenosis
severity category
Odds ratio of suffering an
neurological event in the
change in stenosis severit
Any decrease in stenosis category
(i.e., regression)
0.716 (0.398e1.287)
No change in stenosis category n/a
Increase by 1 stenosis category 1.647 (1.108e2.448)
Increase by 2 stenosis categories 4.73 (2.326e9.632)
a Data derived from Hirt.12
b Odds ratios calculated compared with where no change in yearly racohort.14 Regression was observed in 4% of subjects, 76% of
stenoses remained unchanged, while stenosis progression
occurred in 20% of patients. The 8-year cumulative risk of
ipsilateral stroke was 0% in patients with duplex evidence of
regression (0% pa); 9% where the stenosis was unchanged
(i.e., 1.1% pa), increasing to 16% in patients with stenosis
progression (i.e., 2% pa). Despite stenosis progression being
associated with a doubling of the annual rate of stroke, 40
of the 59 ipsilateral strokes (68%) that occurred during
follow-up affected patients with no evidence of stenosis
progression.14
Hirt12 has recently published a subgroup analysis from
the ACST database, describing the relationship between
stenosis progression and the risk of suffering an ipsilateral
neurological event (i.e., any TIA or stroke) in patients ran-
domized to medical therapy. Baseline stenoses were cate-
gorized into one of ﬁve NASCET measurement based groups
(0e49%; 50e69%; 70e89%; 90e99%; occlusion). The
average annual rate of stenosis progression for the overall
cohort was 5.2%, while the average annual rate of stenosis
regression was 4.5%. Table 4 summarizes the principle
ﬁndings of this analysis. As was observed in ACSRS, stenosis
regression was associated with a low rate of late ipsilateral
events. Stenosis progression by more than two categories
(e.g., from 50e69% to 90e99%) was associated with a
ﬁvefold increase in the risk of ipsilateral neurological events
in the following year. However, it is important to be aware
that the actual numbers of “at risk” patients for this
particular category (n ¼ 50) was very small compared with
the overall cohort under surveillance. It is perhaps more
important to note, however, that the vast majority of ipsi-
lateral events (numerically) occurred in patients with nory during ﬁve years of follow-up in ACST and the risk of suffering an
py.a
ipsilateral
year after a
yb
Number of ipsilateral events
occurring in the year after
a change in stenosis severity
p
12/427 (2.8%) .264
156/1312 (11.9%)
29/463 (6.3%) .014
9/50 (18%) <.001
te of stenosis severity was observed.
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the small numbers of patients with signiﬁcant stenosis
progression in this study, another limiting feature was a
failure to report the risk of late ipsilateral stroke, as Hirt
combined all ipsilateral events together.
ACST has also published a subgroup analysis on the risk of
suffering carotid occlusion and the subsequent risk of
suffering a stroke.15 In the cohort of patients randomized to
medical therapy, the risk of suffering an ipsilateral carotid
occlusion was about 1% per annum. Interestingly, only
13.6% of patients who occluded their carotid artery suf-
fered a stroke at the time of their occlusion, while a further
10% suffered an ipsilateral stroke sometime later during
follow-up.15 In practical terms, this means that for every
700 asymptomatic patients with a 70e99% asymptomatic
stenosis treated medically, seven will occlude their carotid
artery each year, but only one of the 700 will suffer an
ipsilateral stroke, while one further patient will suffer an
ipsilateral stroke at a later date following the occlusion.
Duplex derived plaque visualization
The morphology of carotid plaques, as assessed by ultra-
sound imaging, has traditionally been done by visual (sub-
jective) grading of the plaque’s echo-reﬂection (e.g.,
echogenicity, echolucency) and its echo pattern (e.g., het-
erogeneous or homogeneous). Computerized plaque anal-
ysis was not developed until the 1990s.
The literature contains conﬂicting ﬁndings. Using visual
assessment, ACST observed that asymptomatic patients
with echolucent stenoses did not have an increased risk of
late stroke.5 By contrast, the Tromso study16 observed that
hypoechoic plaques were associated with an increased risk
of late stroke, as did the Cardiovascular Health Study Group
which showed that asymptomatic patients with hypoechoic
carotid stenoses had a threefold increase in late ipsilateral
stroke (OR 2.8; 95% CI 1.4e5.7).17 In the latter study,
however, these higher stroke rates were only observed in
patients with the highest peak systolic velocities (>250 cm/
second) and only 0.5% of the overall study cohort had this
severity of stenosis.18
Visual plaque assessment (types I/II ¼ echolucent; types
III/IV ¼ echogenic) was combined with the presence/
absence of spontaneous embolization using transcranial
Doppler (TCD) in the Asymptomatic Carotid Embolisation
Study (ACES).19 The combination of plaque echolucency and
being embolus positive, signiﬁcantly increased the rate of
ipsilateral stroke after correction for risk factors, stenosis
severity and antiplatelet therapy (OR 10.6; 95% CI 2.98e
37.52).19 Only 6.3% of ACES patients had the combination
of type I/II plaques and had 1 embolus detected, but this
very small cohort of patients had an annual ipsilateral
stroke rate of 8.9% versus 0.8% in the remaining patients.19
Computerized plaque analysis
ACSRS has undertaken a number of computerized plaque
analysis studies after normalization of image data. The Gray
Scale Median (GSM) is a computerized (objective)measurement of the “gray” values of plaque pixels after
image normalization. Image normalization involves an area
of blood being scaled to zero, while the brightest area of the
adventitia is normalized to a gray scale of 190. Following
image normalization, the lower the GSM the more echo-
lucent is the plaque. Conversely, echogenic plaques will
have a higher GSM. In the ACSRS study, asymptomatic
plaques with a GSM >30 had a very low annual rate of
stroke (0.6%). The annual rate of stroke increased to 1.6%
pa in patients with a GSM of 15e30, while patients with a
GSM <15 had a 3.6% annual risk of stroke.20
By contrast, however, Gronholdt et al.21 used a similar
computerized assessment of GSM and found that neither
plaque echolucency (nor severity of stenosis) was predictive
of late ipsilateral stroke or death among 111 asymptomatic
patients with 50e99% stenoses who were followed for 4.4
years.
The ACSRS plaque classiﬁcation (plaque types IeIV) is an
objective modiﬁcation of the GrayeWeale scale and assigns
a plaque type according to its echolucency/echogenicity
based on an objective assessment of pixel gray-scale
values:22 Type 1, uniformly echolucent with <15% of
pixels in the plaque area being occupied by pixels with gray-
scale values >25; Type 2, mainly echolucent where pixels
with gray-scale values >25 occupy 15e50% of the plaque;
Type 3, mainly echogenic with pixels with gray-scale values
>25 occupying 50e85% of the plaque; and Type 4, uni-
formly echogenic with pixels with gray-scale values >25
occupying >85% of the plaque. Asymptomatic patients with
Type 4 plaques had a 0.4% annual risk of stroke, compared
with 0.8% in Type 3 plaques. The annual rate of stroke in
patients with Type 1/2 plaques was 3.0%. Of particular note
was the observation that three-quarters (76%) of late
strokes affecting asymptomatic patients in the ACSRS study
occurred in the 38% of patients (426/1121) who had Type
1/2 plaques.22 To date, the ability of this particular classi-
ﬁcation to predict cohorts of patients with greater (or
lesser) risks of late stroke has not been validated in any
other large scale, natural history study.
Two other parameters were developed by the ACSRS
(plaque area and juxta-luminal black area20). Plaque area
(mm2) is calculated by the imaging software using the dis-
tance scale on the side of the image frame for calibration
and the plaque area outlined by the operator. The largest
juxta-luminal black area (JBA) of the image, deﬁned as the
plaque area with pixels having a gray-scale <25 without a
visible echogenic cap, was outlined and expressed as mm2.
Asymptomatic patients with 50e99% stenoses who had a
plaque area <40 mm2 had a low annual rate of stroke
(1.0%), which increased to 1.4% pa in patients with a plaque
area of 40e80 mm2. However, the highest annual rate of
stroke (4.6% pa) was observed in patients with a plaque
area >80 mm2.
Juxta-luminal black areas represent softer components of
the plaque adjacent to the vessel lumen20 (necrotic core,
lipid, hemorrhage, thrombus). In the ACSRS; a JBA <4 mm2
was associated with a 0.4% annual risk of stroke, which
increased to 1.4% when the JBA was 4e8 mm2. The highest
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with higher JBAs (3.2% pa for a JBA of 8e10 mm2 and 5.0%
pa for a JBA >10 mm2). Overall, patients with a JBA
<8 mm2 had an annual stroke rate of 0.6%, compared to
4.6% pa in patients with a JBA >8 mm2. In a recent blinded
study, logistic regression analysis showed that patients with
a combination of plaque area >95 mm2 and a JBA >6 mm2
had a 90% probability of having a histologically unstable
carotid plaque.23
The ACSRS8,20 has subsequently developed an algorithm
for predicting the likely annual rate of stroke for individual
patients, based upon a multivariate analysis of their
ultrasound-based parameters (Fig. 1). For example, a pa-
tient with an 80e99% asymptomatic stenosis with no his-
tory of contralateral TIA, whose plaque area is <40 mm2
and who has a plaque GSM >30 is predicted to have an
annual stroke rate of 0.5% (low risk, probably best treated
medically). By contrast; someone with an 80e99% stenosis,
but who reports a prior history of contralateral TIA and who
was has a plaque area >80 mm2 and a GSM <25 would be
predicted to have a 10% annual rate of stroke (very high-
risk, would certainly beneﬁt from CEA/CAS).
To date, however, the ability of computerized plaque
derived parameters to predict cohorts of patients withFigure 1. Prediction of annual risk of stroke in patients with 50e
79% or 80e99% asymptomatic carotid stenosis (NASCET mea-
surement method). The annualized risk of stroke is based upon
stenosis severity, the presence or absence of prior contralateral
symptoms and two computerized plaque analyses (plaque area
and Gray Scale Median). Note. From “Time to rethink management
strategies in asymptomatic carotid disease,” by AR Naylor, 2011,
Nature Reviews Cardiology pp. 116e24. Reprinted with
permission.greater (or lesser) risks of suffering a late stroke has not
been validated in any other large scale, natural history
study. Moreover, it remains unclear whether the ability to
predict higher risk cohorts might have been different had
patients received modern “best medical therapy.”
Duplex/MRI derived plaque irregularity
Plaque irregularity has been associated with an increase in
late stroke in asymptomatic patients, although not all pa-
tients in the constituent studies had 50e99% stenoses.
Kitamura et al.24 undertook serial duplex ultrasound sur-
veillance in 1358 Japanese males with no history of cardio-
vascular disease and observed that subjects with plaque
irregularity had an age-adjusted increase in late stroke (OR
7.7; 95% CI 2e30). Kitamura et al.’s ﬁndings were corrobo-
rated by the North Manhattan Stroke Study (1939 patients),
which showed that while only 5.5% of subjects had an
irregular carotid plaque on duplex, the 5-year risk of ischemic
stroke was 1.3% in patients with no evidence of carotid
plaques (i.e., 0.3% stroke risk pa), 3% in those with a smooth
carotid plaque (0.6% pa), increasing to 8.5% in patients with
an irregular plaque (1.7% pa).25 After adjusting for (a) risk
factors, (b) stenosis severity, and (c) plaque thickness, an
irregular carotid plaque was associated with a threefold
excess risk of late stroke (OR 3.1; 95% CI 1.1e8.5). Inter-
estingly, having bilateral plaque irregularity signiﬁcantly
increased the risk of long-term stroke compared to patients
with unilateral plaque irregularity (OR 3.9 (1.4e11)).25
Madani et al.26 performed serial plaque surveillance with
high-resolution ultrasound in 253 asymptomatic patients
with 60e99% carotid stenoses who were treated with
aggressive medical therapy. This group observed that the
presence of three or more micro-plaque ulcers (in total
from both carotid artery plaques) was associated with a
signiﬁcant increase in stroke/death at 3 years, compared
with patients who had fewer or no ulcers (18% vs. 2%,
p ¼ .03). Underhill followed 85 asymptomatic subjects with
50e79% stenoses and no MRI evidence of luminal surface
disruption at baseline. The size of the lipid rich necrotic core
was the strongest predictor for patients developing new
plaque surface disruption/micro-ulceration at a median of
36 months.27
MRI
Esposito-Bauer et al.28 followed 77 asymptomatic patients
with 50e99% stenoses over a median of 44 months. MR
scans were performed at baseline in order to classify pa-
tients according to the AHA plaque classiﬁcation. Nine of 77
patients suffered recurrent ipsilateral events and these only
occurred in patients with AHA plaque types IVeV (plaque
with lipid or necrotic core surrounded by ﬁbrous tissue and
possible calciﬁcation) or type VI (complex plaque with
possible surface defect, hemorrhage or thrombus). No
recurrent cerebral events occurred in patients with plaques
classiﬁed as being stable (AHA types III, VII, and VIII).28
There has been considerable interest in evaluating
whether an MR diagnosis of IPH is predictive of an
638 A.R. Naylor et al.increased risk of stroke in asymptomatic patients. Underhill
et al.27 followed 67 asymptomatic patients with 16e49%
asymptomatic stenoses and observed that lesions with an
MR diagnosis of IPH tended to undergo rapid expansion
with luminal narrowing, while lesions with no MR evidence
of IPH tended to undergo outward expansion in association
with continuous remodeling, leading to preservation of
luminal integrity. Takaya et al.29 followed 154 asymptomatic
patients with 50e79% stenoses and observed that patients
with an MRI diagnosis of thinned/ruptured ﬁbrous caps,
intra-plaque hemorrhage and large lipid cores incurred
higher rates of ipsilateral stroke than patients without these
features. Singh et al.30 undertook a similar study in 98
asymptomatic males with 50e70% asymptomatic stenoses.
Thirty-six had MR evidence of IPH and six suffered ipsilateral
stroke/TIA, compared with 0/62 patients without IPH. A
univariate Cox regression analysis showed that an MR
diagnosis of IPH was associated with a threefold increased
risk of late ipsilateral neurological events (OR 3.6; 95% CI
2.5e4.7, p < .001).
However, there are also unexplained anomalies in the
predictive value of an MR diagnosis of IPH. In Altaf et al.’s31
series, an MR diagnosis of IPH was highly predictive of
recurrent events in the territory ipsilateral to a recently
symptomatic stenosis. However, 58% of these patients also
had MR evidence of IPH in the contralateral asymptomatic
ICA and none suffered a stroke ipsilateral to these lesions
during 36 months of follow-up.TCD diagnosed embolization
A systematic review and meta-analysis of six observational
studies (1144 asymptomatic patients with 70e99% steno-
ses) found that the presence of a single embolus detected
using TCD was associated with an eightfold excess risk of
late stroke (OR 7.6; 95% CI 2.3e24.7).32 There was also
evidence that the introduction of aggressive medical ther-
apy could signiﬁcantly reduce the prevalence and magni-
tude of TCD embolization (from 12.6% to 3.6%), in
association with a signiﬁcant reduction in ipsilateral stroke
and the need for CEA.33
The largest (individual) observational study (ACES) has
now published a subgroup analysis correlating sponta-
neous embolization with plaque morphology and late
stroke risk.19 The combination of plaque echolucency
(deﬁned as ACSRS plaque type I/II20) and being embolus
positive, signiﬁcantly increased the rate of ipsilateral stroke
after correction for risk factors, stenosis severity and an-
tiplatelet therapy (OR 10.6; 95% CI 2.98e37.52).19 Only
6.3% of ACES patients had type I/II plaques and had 1
embolus detected, but this very small cohort of patients
had an annual ipsilateral stroke rate of 8.9% versus 0.8% in
the remaining patients. Interestingly, the ACES trial found
no correlation between plaque lucency, stenosis severity
and embolus status at baseline, suggesting that lucent
plaques became more unstable during follow-up with the
secondary development of spontaneous embolization and
ipsilateral symptoms.19“Silent” infarction on CT
About 20% of patients with asymptomatic carotid stenoses
will have evidence of “silent” infarction on CT/MRI.20 ACSRS
and ACST have performed secondary analyses to establish
whether “silent” infarcts were associated with an increased
risk of late stroke. ACSRS observed that patients with ipsi-
lateral “silent” infarction had a signiﬁcantly higher annual
rate of ipsilateral stroke (3.6% pa), than patients with no
evidence of infarction (1.0% pa; p ¼ .002).34 ACST under-
took a similar study; 1331 patients with evidence of either
ipsilateral infarction on baseline CT/MRI or a history of ce-
rebral symptoms had a 5.8% absolute risk increase in stroke
at 10 years (95% CI 1.8e9.8; p ¼ .004), compared to pa-
tients with no prior symptoms or infarction. No further
information is available regarding this subgroup analysis as
it has only appeared in abstract form.35
Biomarkers
Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is
signiﬁcantly elevated in patients with 70e99% asymptom-
atic carotid stenoses who have evidence of unstable plaque
features on independent histological examination.36 It re-
mains to be seen, however, whether elevated Lp-PLA2
levels can identify high-risk for stroke asymptomatic
patients.
Intracranial disease
Madani et al.26 observed that the presence of asymptom-
atic tandem lesions (intracranial and extracranial) was
associated with a signiﬁcantly higher rate of stroke/TIA/
death at 3 years (p ¼ .001) and stroke and/or TIA at 3 years
(p ¼ .004).
SUMMARY
Asymptomatic patients
There is little evidence that increasing stenosis severity is
associated with an increased risk of late stroke. Parameters
associated with an increased risk of late stroke in asymp-
tomatic patients with carotid disease include: (a) silent
infarction on CT/MRI; (b) stenosis progression; (c) hypo-
echoic plaques or GSM <15; (d) irregular plaques; (e) evi-
dence of spontaneous embolization on TCD; (f) AHA plaque
types IVeV, VI; (g) MR diagnosed IPH; (h) plaque area
>80 mm2; (i) juxta-luminal black area >10 mm2 and (j)
tandem intracranial disease. Clinical features associated
with an increased risk of late stroke include (k) a history of
prior ipsilateral and contralateral TIA/minor stroke.
Clinical/imaging parameters associated with a lower in-
termediate/late risk of stroke include: (a) patients aged >75
years; (b) stenosis regression or no progression; (c) a GSM
>30; and (d) AHA plaque types III, VII, and VIII.
However, many of the parameters that have been re-
ported to be associated with a greater (or lesser) risk of
suffering a stroke have not been subject to independent
validation and most of the patients in the constituent
studies were not receiving what would now be considered
Predicting stroke in asymptomatic patients 639optimal medical therapy. There is also the unanswered
question relating to dynamic plaque changes; i.e., can a
single “snap-shot” be used to predict late stroke risk or is
serial surveillance required? It is, therefore, essential that
any new natural history studies or randomized trials in
asymptomatic patients includes an analysis of one or more
of these imaging strategies in order to identify the small
cohort of “high risk for stroke” patients who will beneﬁt
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